Patents by Inventor Michael Louis Robert Deligny

Michael Louis Robert Deligny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11345662
    Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: May 31, 2022
    Assignee: UCB Pharma GmbH
    Inventors: Christa E. Mueller, Cécile Pegurier, Michael Louis Robert Deligny, Ali El-Tayeb, Joerg Hockemeyer, Marie Ledecq, Joël Mercier, Laurent Provins, Nader M. Boshta, Sanjay Bhattarai, Vigneshwaran Namasivayam, Mario Funke, Lukas Schwach, Sabrina Gollos, Daniel Von Laufenberg, Anaïs Barré
  • Publication number: 20220127227
    Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.
    Type: Application
    Filed: January 5, 2022
    Publication date: April 28, 2022
    Inventors: Christa E. MUELLER, Cécile PEGURIER, Michael Louis Robert DELIGNY, Ali EL-TAYEB, Joerg HOCKEMEYER, Marie LEDECQ, Joël MERCIER, Larurent PROVINS, Nader M. BOSHTA, Sanjay BHATTARAI, Vigneshwaran NAMASIVAYAM, Mario FUNKE, Lukas SCHWACH, Sabrina GOLLOS, Daniel VON LAUFENBERG, Anaïs BARRÉ
  • Publication number: 20220048858
    Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.
    Type: Application
    Filed: October 20, 2021
    Publication date: February 17, 2022
    Inventors: Christa E. MUELLER, Cécile PEGURIER, Michael Louis Robert DELIGNY, Ali EL-TAYEB, Joerg HOCKEMEYER, Marie LEDECQ, Joël MERCIER, Larurent PROVINS, Nader M. BOSHTA, Sanjay BHATTARAI, Vigneshwaran NAMASIVAYAM, Mario FUNKE, Lukas SCHWACH, Sabrina GOLLOS, Daniel Von Laufenberg, Anaïs BARRÉ
  • Patent number: 10766906
    Abstract: Disclosed are substituted fused hexacyclic benzimidazole derivatives of Formula (I) wherein the variables A, B, D, X, M, Q, n, p, q, Z, E, R5, and R12 are defined herein. These compounds are potent modulators of human TNF? activity and of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 8, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Teresa De Haro Garcia, Michael Louis Robert Deligny, Jag Paul Heer, Helen Tracey Horsley, Sophie Jadot, Jean Keyaerts
  • Patent number: 10669286
    Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: June 2, 2020
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer
  • Patent number: 10654861
    Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 19, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer, Jean Keyaerts, Luce Elsa Lepissier, Martin Alexander Lowe
  • Publication number: 20190345104
    Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.
    Type: Application
    Filed: December 27, 2017
    Publication date: November 14, 2019
    Applicant: UCB Pharma GmbH
    Inventors: Christa E. MUELLER, Cécile PEGURIER, Michael Louis Robert DELIGNY, Ali EL-TAYEB, Joerg HOCKEMEYER, Marie LEDECQ, Joël MERCIER, Laurent PROVINS, Nader M. BOSHTA, Sanjay BHATTARAI, Vigneshwaran NAMASIVAYAM, Mario FUNKE, Lukas SCHWACH, Sabrina GOLLOS, Daniel von LAUFENBERG, Anaïs BARRÉ
  • Publication number: 20190119302
    Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 25, 2019
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer
  • Publication number: 20190100525
    Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 4, 2019
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer, Jean Keyaerts, Luce Elsa Lepissier, Martin Alexander Lowe
  • Publication number: 20190100526
    Abstract: A series of substituted fused hexacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 4, 2019
    Applicants: UCB Biopharma SPRL, Sanofi
    Inventors: Teresa De Haro Garcia, Michael Louis Robert Deligny, Jag Paul Heer, Helen Tracey Horsley, Sophie Jadot, Jean Keyaerts
  • Patent number: 9926313
    Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: March 27, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Fabien Claude Lecomte, John Robert Porter
  • Publication number: 20160304513
    Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Fabien Claude Lecomte, John Robert Porter